Assembly Biosciences (NASDAQ:ASMB) Issues Earnings Results, Beats Expectations By $2.99 EPS

Assembly Biosciences (NASDAQ:ASMB) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99, FiscalAI reports. The firm had revenue of $42.47 million for the quarter, compared to analysts’ expectations of $7.42 million. Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%.

Assembly Biosciences Stock Down 0.0%

Shares of Assembly Biosciences stock traded down $0.01 during trading hours on Thursday, reaching $27.51. 54,940 shares of the company’s stock were exchanged, compared to its average volume of 100,312. The business has a fifty day moving average of $28.23 and a two-hundred day moving average of $29.55. The company has a market capitalization of $435.13 million, a P/E ratio of -5.74 and a beta of 1.11. Assembly Biosciences has a 1 year low of $7.75 and a 1 year high of $39.71.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Mizuho set a $40.00 target price on shares of Assembly Biosciences and gave the company an “outperform” rating in a research report on Thursday, November 20th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research report on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.75.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtus Investment Advisers LLC purchased a new stake in Assembly Biosciences during the 4th quarter valued at about $251,000. Susquehanna Portfolio Strategies LLC purchased a new position in Assembly Biosciences in the 4th quarter worth approximately $473,000. Superstring Capital Management LP acquired a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $2,220,000. Millennium Management LLC boosted its holdings in shares of Assembly Biosciences by 354.6% during the 4th quarter. Millennium Management LLC now owns 98,221 shares of the biopharmaceutical company’s stock worth $3,340,000 after purchasing an additional 76,613 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of Assembly Biosciences by 11.3% in the fourth quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company’s stock valued at $28,540,000 after purchasing an additional 85,299 shares in the last quarter. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.